Finasteride
Active ingredient · 2 therapeutic classes
Sold as PROSCAR · PROPECIA
- Drug class
- Testosterone-5-Alpha Reductase Inhibitors
- Availability
- Prescription only
- Routes
- Oral
- Markets covered
- 3
- Products on record
- 84
- FDA reports (12 mo)
- 4,697
Overview
Finasteride is an active pharmaceutical ingredient in the Testosterone-5-Alpha Reductase Inhibitors group (G04CB). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 34 | May 22, 2026 |
| US United States | FDA | 25 | May 12, 2026 |
| CA Canada | Health Canada | 25 | May 20, 2026 |
GBUnited Kingdom· MHRA
34 products
Uses
Finasteride 5 mg Tablets are indicated for the treatment and control of benign prostatic hyperplasia (BPH) in patients with an enlarged prostate to: - cause regression of the enlarged prostate, improve urinary flow and improve the symptoms associated with BPH.
- reduce the incidence of acute urinary retention and the need for surgery including transurethral resection of the prostate (TURP) and prostatectomy.
How to take
USUnited States· FDA
25 products
Uses
1 INDICATIONS & USAGE Finasteride tablets USP are indicated for the treatment of male pattern hair loss (androgenetic alopecia) in MEN ONLY. Efficacy in bitemporal recession has not been established. Finasteride tablets USP are not indicated for use in women.
• Finasteride tablets USP are 5α-reductase inhibitors indicated for the treatment of male pattern hair loss (androgenetic alopecia) in MEN ONLY ( 1 ). 1 ).
How to take
CACanada· Health Canada
25 products
Uses
• PROSCAR® (finasteride tablets, USP) is a Type II 5α-reductase inhibitor, indicated as monotherapy for the treatment and control of benign prostatic hyperplasia (BPH) and for the prevention of urologic events to: - Reduce the risk of acute urinary retention; - Reduce the risk of surgery including transurethral resection of the prostate (TURP) and prostatectomy.
• PROSCAR causes regression of the enlarged prostate, improves urinary flow and improves the symptoms associated with BPH. • PROSCAR administered in combination with the alpha-blocker doxazosin is indicated to reduce the risk of symptomatic progression of BPH (a confirmed ≥ 4 point increase in American Urological Association (AUA) symptom score).
Limitations of Use • PROSCAR is not approved for the prevention of prostate cancer. Patients with an enlarged prostate are the appropriate candidates for therapy with PROSCAR. 1 Pediatrics (<18 years of age) No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use (see 14 CLINICAL TRIALS).
Drug interactions
Known interactions involving Finasteride. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 317. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL458410012 · revised December 9, 2024
- [2]FDA DailyMed · 00e934bb-c15b-49… · revised July 28, 2017 [PDF]
- [3]Health Canada (DPD) · 02010909 · revised March 22, 2025
- [4]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.